Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 4/2021

01.04.2021 | Autoimmunity (TK Tarrant, Section Editor)

Paget’s Disease of Bone: Osteoimmunology and Osteoclast Pathology

verfasst von: Emily M. Rabjohns, Katlyn Hurst, Arin Ghosh, Maria C. Cuellar, Rishi R. Rampersad, Teresa K. Tarrant

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to recognize clinical features of Paget’s disease of bone and to describe how the osteoclast, a myeloid-derived cell responsible for bone resorption, contributes to the disease.

Recent Findings

Recent studies have identified several variants in SQSTM1, OPTN, and other genes that may predispose individuals to Paget’s disease of bone; studies of these genes and their protein products have elucidated new roles for these proteins in bone physiology.

Summary

Understanding the pathologic mechanisms in the Pagetic osteoclast may lead to the identification of future treatment targets for other inflammatory and autoimmune diseases characterized by abnormal bone erosion and/or osteoclast activation.
Literatur
1.
Toodayan N. The Paget bicentenary: an Australian perspective. J Med Biogr. 2018;26(3):164–71.PubMedCrossRef
2.
Sabharwal R, Gupta S, Sepolia S, Panigrahi R, Mohanty S, Subudhi SK, et al. An insight in to Paget’s disease of bone. Niger J Surg. 2014;20(1):9–15.PubMedPubMedCentral
3.
Singer FR. Paget’s Disease of Bone. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA) 2000.
4.••
Daroszewska A, Rose L, Sarsam N, Charlesworth G, Prior A, Rose K, et al. Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62(P394L) mouse model of Paget’s disease. Dis Model Mech. 2018;11(9):dmm035576 Comment: primary research of a p62 mutation mouse model of Paget’s disease.PubMedPubMedCentralCrossRef
5.
6.
7.
Mays S. Archaeological skeletons support a northwest European origin for Paget’s disease of bone. J Bone Miner Res. 2010;25(8):1839–41.PubMedCrossRef
8.
Kesterke MJ, Judd MA. A microscopic evaluation of Paget’s disease of bone from a Byzantine monastic crypt in Jordan. Int J Paleopathol. 2019;24:293–8.PubMedCrossRef
9.
Rogers J, Jeffrey DR, Watt I. Paget’s disease in an archeological population. J Bone Miner Res. 2002;17(6):1127–34.PubMedCrossRef
10.
Waldron HA. Recalculation of secular trends in Paget’s disease. J Bone Miner Res. 2004;19(3):523.PubMedCrossRef
11.
Pusch CM, Czarnetzki A. Archaeology and prevalence of Paget’s disease. J Bone Miner Res. 2005;20(8):1484 author reply 5.PubMedCrossRef
12.
Shaw B, Burrell CL, Green D, Navarro-Martinez A, Scott D, Daroszewska A, et al. Molecular insights into an ancient form of Paget’s disease of bone. Proc Natl Acad Sci U S A. 2019;116(21):10463–72.PubMedPubMedCentralCrossRef
13.
Wermers RA, Tiegs RD, Atkinson EJ, Achenbach SJ, Melton LJ 3rd. Morbidity and mortality associated with Paget’s disease of bone: a population-based study. J Bone Miner Res. 2008;23(6):819–25.PubMedPubMedCentralCrossRef
14.
15.
Tan A, Ralston SH. Clinical presentation of Paget’s disease: evaluation of a contemporary cohort and systematic review. Calcif Tissue Int. 2014;95(5):385–92.PubMedCrossRef
16.
17.
Alvarez L, Guanabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget’s disease. J Bone Miner Res. 1995;10(3):458–65.PubMedCrossRef
18.
Gennari L, Rendina D, Falchetti A, Merlotti D. Paget’s disease of bone. Calcif Tissue Int. 2019;104(5):483–500.PubMedCrossRef
19.
Ralston SH, Corral-Gudino L, Cooper C, Francis RM, Fraser WD, Gennari L, et al. Diagnosis and management of paget’s disease of bone in adults: a clinical guideline. J Bone Miner Res. 2019;34(4):579–604.PubMedCrossRef
20.
Seton M. Paget disease of bone: diagnosis and drug therapy. Cleve Clin J Med. 2013;80(7):452–62.PubMedCrossRef
21.
Seitz S, Priemel M, Zustin J, Beil FT, Semler J, Minne H, et al. Paget’s disease of bone: histologic analysis of 754 patients. J Bone Miner Res. 2009;24(1):62–9.PubMedCrossRef
22.
Rebel A, Malkani K, Basle M, Bregeon C. Is Paget’s disease of bone a viral infection? Calcif Tissue Res. 1977;22(Suppl):283–6.PubMed
23.
Mills BG, Singer FR. Nuclear inclusions in Paget’s disease of bone. Science. 1976;194(4261):201–2.PubMedCrossRef
24.
Nebot Valenzuela E, Pietschmann P. Epidemiology and pathology of Paget’s disease of bone - a review. Wien Med Wochenschr. 2017;167(1-2):2–8.PubMedCrossRef
25.
Reid IR. Recent advances in understanding and managing Paget’s disease. F1000Res. 2019;8.
26.
Stanislavsky A Polyostotic Paget Disease 2011 [Available from: https://​radiopaedia.​org/​cases/​polyostotic-paget-disease?​lang=​us.​
27.
Singer FR. Paget’s disease of bone-genetic and environmental factors. Nat Rev Endocrinol. 2015;11(11):662–71.PubMedCrossRef
28.
Singer FR, Bone HG 3rd, Hosking DJ, Lyles KW, Murad MH, Reid IR, et al. Paget’s disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408–22.PubMedCrossRef
29.
Winn N, Lalam R, Cassar-Pullicino V. Imaging of Paget’s disease of bone. Wien Med Wochenschr. 2017;167(1-2):9–17.PubMedCrossRef
30.
31.
Lyles KW, Gold DT, Newton RA, Parekh S, Shipp KM, Pieper CF, et al. Peyronie’s disease is associated with Paget’s disease of bone. J Bone Miner Res. 1997;12(6):929–34.PubMedCrossRef
32.
Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med. 2005;353(9):898–908.PubMedCrossRef
33.
Seton M, Krane SM. Use of zoledronic acid in the treatment of Paget’s disease. Ther Clin Risk Manag. 2007;3(5):913–8.PubMedPubMedCentral
34.
Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22(1):142–8.PubMedCrossRef
35.
Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, et al. Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab. 1996;81(3):961–7.PubMed
36.
Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of bone. Bone. 2004;34(4):747–54.PubMedCrossRef
37.
Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Paget’s Risedronate/Etidronate Study Group. Am J Med. 1999;106(5):513–20.PubMedCrossRef
38.
Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget’s disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int. 2004;75(3):189–96.PubMedCrossRef
39.
40.
Hocking LJ, Lucas GJ, Daroszewska A, Mangion J, Olavesen M, Cundy T, et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s disease. Hum Mol Genet. 2002;11(22):2735–9.PubMedCrossRef
41.
Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res. 2011;26(9):2261–70.PubMedCrossRef
42.
Cundy T, Maslowski K, Grey A, Reid IR. Durability of response to Zoledronate treatment and competing mortality in Paget’s disease of bone. J Bone Miner Res. 2017;32(4):753–6.PubMedCrossRef
43.
Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J Bone Miner Res. 2010;25(1):20–31.PubMedCrossRef
44.
Reid IR, Sharma S, Kalluru R, Eagleton C. Treatment of Paget’s disease of bone with denosumab: case report and literature review. Calcif Tissue Int. 2016;99(3):322–5.PubMedCrossRef
45.
Barry HC. Orthopedic aspects of Paget’s disease of bone. Arthritis Rheum. 1980;23(10):1128–30.PubMedCrossRef
46.
Bidner S, Finnegan M. Femoral fractures in Paget’s disease. J Orthop Trauma. 1989;3(4):317–22.PubMedCrossRef
47.
Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget’s disease of bone. Bone. 2006;39(4):954–8.PubMedCrossRef
48.
Parvizi J, Klein GR, Sim FH. Surgical management of Paget’s disease of bone. J Bone Miner Res. 2006;21(Suppl 2):P75–82.PubMedCrossRef
49.
Calderoni P, Ferruzzi A, Andreoli I, Gualtieri G. Hip arthroplasty in coxarthrosis secondary to Paget’s disease. Chir Organi Mov. 2002;87(1):43–8.PubMed
50.
Wootton R, Reeve J, Spellacy E, Tellez-Yudilevich M. Skeletal blood flow in Paget’s disease of bone and its response to calcitonin therapy. Clin Sci Mol Med. 1978;54(1):69–74.PubMed
51.
Roodman GD. Insights into the pathogenesis of Paget’s disease. Ann N Y Acad Sci. 2010;1192:176–80.PubMedCrossRef
52.
Numan MS, Jean S, Dessay M, Gagnon E, Amiable N, Brown JP, et al. Gene-environment interactions in Paget’s disease of bone. Joint Bone Spine. 2019;86(3):373–80.PubMedCrossRef
53.
Haddaway MJ, Davie MW, McCall IW, Howdle S. Effect of age and gender on the number and distribution of sites in Paget’s disease of bone. Br J Radiol. 2007;80(955):532–6.PubMedCrossRef
54.
Beyens G, Daroszewska A, de Freitas F, Fransen E, Vanhoenacker F, Verbruggen L, et al. Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene, TNFRSF11B, and Paget’s disease of bone. J Bone Miner Res. 2007;22(7):1062–71.PubMedCrossRef
55.••
Wong SW, Huang BW, Hu X, Ho Kim E, Kolb JP, Padilla RJ, et al. Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget’s disease. Cell Death Differ. 2020;27(1):71–84 Comment: primary research of an optineurin-deficient mouse model of Paget’s disease.PubMedCrossRef
56.
Morales-Piga AA, Rey-Rey JS, Corres-Gonzalez J, Garcia-Sagredo JM, Lopez-Abente G. Frequency and characteristics of familial aggregation of Paget’s disease of bone. J Bone Miner Res. 1995;10(4):663–70.PubMedCrossRef
57.
Seton M, Choi HK, Hansen MF, Sebaldt RJ, Cooper C. Analysis of environmental factors in familial versus sporadic Paget’s disease of bone--the New England Registry for Paget’s Disease of Bone. J Bone Miner Res. 2003;18(8):1519–24.PubMedCrossRef
58.
Merashli M, Jawad A. Paget’s Disease of Bone among Various Ethnic Groups. Sultan Qaboos Univ Med J. 2015;15(1):e22–6.PubMedPubMedCentral
59.••
Cundy T. Paget’s disease of bone. Metabolism. 2018;80:5–14 Comment: recent comprehensive review of Paget’s Disease of Bone.PubMedCrossRef
60.
Merlotti D, Gennari L, Galli B, Martini G, Calabro A, De Paola V, et al. Characteristics and familial aggregation of Paget’s disease of bone in Italy. J Bone Miner Res. 2005;20(8):1356–64.PubMedCrossRef
61.
Audet MC, Jean S, Beaudoin C, Guay-Belanger S, Dumont J, Brown JP, et al. Environmental factors associated with familial or non-familial forms of Paget’s disease of bone. Joint Bone Spine. 2017;84(6):719–23.PubMedCrossRef
62.
Michou L, Collet C, Morissette J, Audran M, Thomas T, Gagnon E, et al. Epidemiogenetic study of French families with Paget’s disease of bone. Joint Bone Spine. 2012;79(4):393–8.PubMedCrossRef
63.
Siris ES. Epidemiological aspects of Paget’s disease: family history and relationship to other medical conditions. Semin Arthritis Rheum. 1994;23(4):222–5.PubMedCrossRef
64.
Barker DJ, Gardner MJ. Distribution of Paget’s disease in England, Wales and Scotland and a possible relationship with vitamin D deficiency in childhood. Br J Prev Soc Med. 1974;28(4):226–32.PubMedPubMedCentral
65.
Lever JH. Paget’s disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: a speculative hypothesis. Bone. 2002;31(3):434–6.PubMedCrossRef
66.
Lopez-Abente G, Morales-Piga A, Elena-Ibanez A, Rey-Rey JS, Corres-Gonzalez J. Cattle, pets, and Paget’s disease of bone. Epidemiology. 1997;8(3):247–51.PubMedCrossRef
67.
Ralston SH, Layfield R. Pathogenesis of Paget disease of bone. Calcif Tissue Int. 2012;91(2):97–113.PubMedCrossRef
68.
Singer FR. Update on the viral etiology of Paget’s disease of bone. J Bone Miner Res. 1999;14(Suppl 2):29–33.PubMedCrossRef
69.
Ehrlich LA, Roodman GD. The role of immune cells and inflammatory cytokines in Paget’s disease and multiple myeloma. Immunol Rev. 2005;208:252–66.PubMedCrossRef
70.
Matthews BG, Afzal MA, Minor PD, Bava U, Callon KE, Pitto RP, et al. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget’s disease. J Clin Endocrinol Metab. 2008;93(4):1398–401.PubMedCrossRef
71.
Visconti MR, Usategui-Martin R, Ralston SH. Antibody response to Paramyxoviruses in Paget’s disease of bone. Calcif Tissue Int. 2017;101(2):141–7.PubMedPubMedCentralCrossRef
72.
Ralston SH, Afzal MA, Helfrich MH, Fraser WD, Gallagher JA, Mee A, et al. Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget’s disease of bone. J Bone Miner Res. 2007;22(4):569–77.PubMedCrossRef
73.
Helfrich MH, Hobson RP, Grabowski PS, Zurbriggen A, Cosby SL, Dickson GR, et al. A negative search for a paramyxoviral etiology of Paget’s disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res. 2000;15(12):2315–29.PubMedCrossRef
74.
Birch MA, Taylor W, Fraser WD, Ralston SH, Hart CA, Gallagher JA. Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bone. J Bone Miner Res. 1994;9(1):11–6.PubMedCrossRef
75.
76.••
Tsukasaki M, Takayanagi H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol. 2019;19(10):626–42 Comment: recent review of osteoimmunology.PubMedCrossRef
77.
Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood. 2007;109(9):3839–48.PubMedPubMedCentralCrossRef
78.
79.
80.
Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006;12(6):657–64.PubMedCrossRef
81.••
Okamoto K, Nakashima T, Shinohara M, Negishi-Koga T, Komatsu N, Terashima A, et al. Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol Rev. 2017;97(4):1295–349 Comment: recent reivew of osteoimmunology.PubMedCrossRef
82.
83.••
Brozowski JM, Billard MJ, Tarrant TK. Targeting the molecular and cellular interactions of the bone marrow niche in immunologic disease. Curr Allergy Asthma Rep. 2014;14(2):402 Comment: review of the bone marrow niche components.PubMedPubMedCentralCrossRef
84.••
Madel MB, Ibanez L, Wakkach A, de Vries TJ, Teti A, Apparailly F, et al. Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions. Front Immunol. 2019;10:1408 Comment: recent review on osteoclast physiology and roles in immunology.PubMedPubMedCentralCrossRef
85.
86.
Daroszewska A, van’t Hof RJ, Rojas JA, Layfield R, Landao-Basonga E, Rose L, et al. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget’s disease-like disorder in mice. Hum Mol Genet. 2011;20(14):2734–44.PubMedCrossRef
87.
Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70(6):1582–8.PubMedPubMedCentralCrossRef
88.
Albagha OM, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie R, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone. Nat Genet. 2010;42(6):520–4.PubMedPubMedCentralCrossRef
89.
Obaid R, Wani SE, Azfer A, Hurd T, Jones R, Cohen P, et al. Optineurin negatively regulates osteoclast differentiation by modulating NF-kappaB and interferon signaling: implications for Paget’s disease. Cell Rep. 2015;13(6):1096–102.PubMedPubMedCentralCrossRef
90.
Zhu G, Wu CJ, Zhao Y, Ashwell JD. Optineurin negatively regulates TNFalpha- induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP. Curr Biol. 2007;17(16):1438–43.PubMedCrossRef
91.
Silva IAL, Conceicao N, Gagnon E, Caiado H, Brown JP, Gianfrancesco F, et al. Effect of genetic variants of OPTN in the pathophysiology of Paget’s disease of bone. Biochim Biophys Acta Mol basis Dis. 2018;1864(1):143–51.PubMedCrossRef
92.
Nakatsuka K, Nishizawa Y, Ralston SH. Phenotypic characterization of early onset Paget’s disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res. 2003;18(8):1381–5.PubMedCrossRef
93.
Iwamoto SJ, Rothman MS, Duan S, Baker JC, Mumm S, Whyte MP. Early-onset Paget’s disease of bone in a Mexican family caused by a novel tandem duplication (77dup27) in TNFRSF11A that encodes RANK. Bone. 2020;133:115224.PubMedPubMedCentralCrossRef
94.
Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24(1):45–8.PubMedCrossRef
95.
Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, et al. Osteoprotegerin deficiency and juvenile Paget’s disease. N Engl J Med. 2002;347(3):175–84.PubMedCrossRef
96.
Daroszewska A, Hocking LJ, McGuigan FE, Langdahl B, Stone MD, Cundy T, et al. Susceptibility to Paget’s disease of bone is influenced by a common polymorphic variant of osteoprotegerin. J Bone Miner Res. 2004;19(9):1506–11.PubMedCrossRef
97.
Daroszewska A, Ralston SH. Genetics of Paget’s disease of bone. Clin Sci (Lond). 2005;109(3):257–63.CrossRef
98.
99.
100.
Chamoux E, Couture J, Bisson M, Morissette J, Brown JP, Roux S. The p62 P392L mutation linked to Paget’s disease induces activation of human osteoclasts. Mol Endocrinol. 2009;23(10):1668–80.PubMedPubMedCentralCrossRef
101.
Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, et al. Interleukin 6. A potential autocrine/paracrine factor in Paget’s disease of bone. J Clin Invest. 1992;89(1):46–52.PubMedPubMedCentralCrossRef
Metadaten
Titel
Paget’s Disease of Bone: Osteoimmunology and Osteoclast Pathology
verfasst von
Emily M. Rabjohns
Katlyn Hurst
Arin Ghosh
Maria C. Cuellar
Rishi R. Rampersad
Teresa K. Tarrant
Publikationsdatum
01.04.2021
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 4/2021
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-021-01001-2

Weitere Artikel der Ausgabe 4/2021

Current Allergy and Asthma Reports 4/2021 Zur Ausgabe

Rhinosinusitis (J Mullol, Section Editor)

Multidisciplinary Care for Severe or Uncontrolled Chronic Upper Airway Diseases

Rhinosinusitis (J Mullol, Section Editor)

Herbal Medicines for Allergic Rhinitis: a Systematic Review and Meta-analysis

Occupational Allergies (JA Poole, Section Editor)

What Is New in Occupational Allergic Contact Dermatitis in the Year of the COVID Pandemic?

Immunotherapy and Immunomodulators (B Vickery, Section Editor)

How to Incorporate Oral Immunotherapy into Your Clinical Practice

Autoimmunity (TK Tarrant, Section Editor)

Fatal Anaphylaxis: Epidemiology and Risk Factors

Occupational Allergies (JA Poole, Section Editor)

Nutritional Factors in Occupational Lung Disease

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise